AMG 509

DRUG2 trials

Sponsors

Amgen Inc., Amgen

Conditions

Metastatic castration-resistant prostate cancer (mCRPC)Prostate Cancer

Phase 1

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT04221542

AmgenProstate Cancer

Start: 2020-03-04End: 2032-03-21Target: 479Updated: 2026-08-21

Phase 3

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

RecruitingCTIS2025-520555-89-00

Amgen Inc.Metastatic castration-resistant prostate cancer (mCRPC)

Start: 2025-11-14Target: 295Updated: 2025-11-13

Related Papers

Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.

Journal of Clinical Oncology2026-05-27

A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.

Journal of Clinical Oncology2025-02-101 citations

A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.

Journal of Clinical Oncology2025-02-10

Abstract B058: Exploring the oncogenic role of six-transmembrane epithelial antigen of the prostate in the context of androgen receptor signaling

Cancer Research2023-06-02

A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2022-06-018 citations

Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-02-204 citations

718 AMG 509, a STEAP1 x CD3 bispecific XmAb<sup>®</sup> 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Regular and Young Investigator Award Abstracts2020-11-014 citations

Abstract DDT02-03: AMG 509: A novel, humanized, half-Life extended, bispecific STEAP1 × CD3 T cell recruiting XmAb® 2+1 antibody

Cancer Research2020-08-1514 citations

Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-05-2011 citations